DOCSLIB.ORG

Erosive Lichen Planus Affecting the Vulva

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

EROSIVE LICHEN PLANUS AFFECTING THE VULVA: Defining the disease, developing outcome measures and designing a randomised controlled trial Rosalind C Simpson BMedSci, BMBS, MRCP(UK) Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy December 2014 Abstract Erosive lichen planus (ELP) is a chronic, inflammatory, scarring skin condition that occurs predominantly on the mucosal surfaces of the mouth and genital region. It is believed to be an autoimmune condition although the exact pathogenesis remains unclear. This thesis focuses on ELP affecting the vulvovaginal region (ELPV). This is a rare condition with unknown incidence and prevalence. It causes painful raw areas at the vaginal entrance and subsequent scarring leads to anatomical changes with narrowing of the vaginal canal. Symptoms lead to difficulty in normal daily activities such as walking/sitting, washing, going to the toilet and can prevent normal sexual function. There is risk of cancerous change in affected skin of 1-3%. A Cochrane Systematic Review of interventions for mucosal erosive lichen planus, published in 2012, found no randomised controlled trials (RCT) on which to base treatment for ELPV. Evidence for treatments has historically been based upon retrospective case- series and case reports. Retrospective case series suggest that super-potent topical corticosteroids an effective first-line therapy, although one third of patients fail to respond adequately and require I Abstract escalation of therapy. There is no agreement for which second-line agents should be used and this is where the greatest clinical need for therapeutic guidance exists. The objective of this PhD was to begin to standardise practice for the management of people with ELPV and then develop a pragmatic protocol for those individuals who had failed to adequately respond to first line therapy with super-potent topical corticosteroids. Initial work focused on current practice in the management of lichen planus, how response to therapy was documented and which outcome measures were routinely used. The following steps were taken to finally inform the design of an RCT to determine optimal second-line therapy for EVLP resistant to topical steroids A multi-centre retrospective review and audit of case notes to assess current clinical management in the UK. Variation in practice was found and uncertainties were identified. These uncertainties comprised methods of diagnosing the condition, outcome measures used to assess severity and impact of the disease and therapeutic choices. A qualitative investigation into UK clinicians’ views and principles of management of vulval erosive lichen planus. This involved interviews with 25 UK clinicians and aimed to begin to address the uncertainties identified by the retrospective case note study. II Abstract An international multi-disciplinary consensus exercise. This was performed to agree a set of diagnostic criteria for ELPV that are acceptable to the clinical community. A systematic review of the literature to assess existing outcome measure tools that have been used in randomised controlled trials of vulval skin disorders. A survey of a national patient group, the UK Lichen Planus Society which identified preliminary information about living with ELPV from the patient’s perspective. Focus groups with patients. The themes identified from the UK Lichen planus Society survey, plus findings from the systematic review of outcome measures, were subsequently explored in greater detail through focus group work with patients. Focus groups were also used to obtain patient input into the proposed future RCT protocol Evidence from this work has informed a randomised controlled trial (RCT) developed with input from patients and clinicians to pragmatically answer an important question of clinical significance The resulting trial is a multi-centre, four-armed, open-label, pragmatic randomised controlled trial which will run in the secondary care setting. The trial will compare the medications hydroxychloroquine, methotrexate and mycophenolate mofetil against a standard care group of clobetasol propionate 0.05% plus a short course of oral prednisolone. These therapies were identified by III Abstract clinicians as likely to be most effective in clinical practice. However, amongst expert clinicians, there was no clearly preferred agent and insufficient data existed within the literature to demonstrate efficacy of any of these medications. It was therefore impossible to pick one comparator alone to test in a two-armed, placebo controlled RCT. As the disease is rare but chronic and resources limited in it was decided that a four-armed study would be the most appropriate as it would conserve patient numbers compared to running separate trials, and would give information on the three of the most commonly used systemic agents likely to be most effective. The primary outcome measure will be the proportion of participants responding to therapy at 6 months. This will be measured by a Patient Global Assessment score of 0 or 1 on a 4-point scale, and an Investigator Global Assessment of improvement from baseline judged by clinical images. The randomised controlled trial protocol has received ethical approval by the National Research Ethics Committee and the necessary regulatory documentation has been completed for the trial to commence in summer 2014. Impact of this research: This will be the first randomised controlled trial to test systemic agents for patients with vulval erosive lichen planus and will add to the existing evidence base. The impact of this work will potentially IV Abstract extend beyond improving care for patients with ELPV as the methodologies employed to develop the RCT protocol, and the trial design itself, may act as a template for clinical research into the therapeutic management of other rare inflammatory conditions. V Publications and presentations arising from this work Peer reviewed publications Simpson RC, Thomas KS, Murphy R. Comment on "management of vulvovaginal lichen planus: a new approach”. J Low Genit Tract Dis. 2014 Jan;18(1):E23-4. Simpson RC, Thomas KS, Murphy R. Outcome measures for vulval skin conditions: A systematic review of randomised controlled trials. Br J Dermatol. 2013 Sep;169(3):494-5 Simpson RC, Thomas KS, Murphy R. Vulval Erosive Lichen Planus: A qualitative investigation of UK clinician views and principles of management. Br J Dermatol. 2013 Jul;169(1):226-7. Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic Criteria for Erosive Lichen Planus Affecting the Vulva: An international electronic-Delphi Consensus Exercise. Br J Dermatol. 2013 Aug;169(2):337-43 Simpson RC, Murphy R. Critically Appraised Topic - Is vulval erosive lichen planus a premalignant condition? Arch Dermatol. 2012 Nov 1;148(11):1314-6. VII Publications and presentations Simpson RC, Murphy R et al. Real life experience from a UK multi- centre case note audit; management of vulval erosive lichen planus. Br J Dermatol. 2012 Jul;167(1):85-91. Simpson RC, Murphy R. Considerations for Disease Impact and Outcome Measures in Vulvar Disease. J Low Genit Tract Dis. 2012 Oct;16(4):460-3. Book chapter Simpson RC, Murphy R, Nunns D: Vulval lichen sclerosus, erosive lichen planus and vulvodynia. In Williams HC , Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B (eds) Evidence Based Dermatology 3rd Edition Chapter 72, Wiley Blackwell Publishers 2014. Conference abstracts Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for erosive lichen planus affecting the vulva: An electronic-Delphi consensus exercise. Br J Dermatol 2013;169 (Suppl 1):4 Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for erosive lichen planus affecting the vulva: An electronic-Delphi consensus exercise. Journal of Investigative Dermatology 2013; 133 (Suppl.):S38 VIII Publications and presentations Cheng S, Simpson R, Kirtschig G, Cooper S, Silcocks P, Thornhill P, Murphy R. A Systematic Review of Interventions for Erosive Lichen Planus Affecting Mucosal Sites. J Low Gen Tract Dis Oct 2011; (Suppl): S5. Oral presentations British Society for the Study of Vulval Disease (BSSVD) Biannual Meeting, Glasgow, March 2014 Update on vulval erosive lichen planus randomised controlled trial School of Clinical Sciences Research Committee Workshop, Nottingham, July 2013 Patient and Public Involvement in the Clinical Research Cycle British Association of Dermatologists Annual Meeting, Liverpool, July 2013 Diagnostic criteria for erosive lichen planus affecting the vulva: An electronic-Delphi consensus exercise. Sue Watson Postgraduate Oral Presentation Event, University of Nottingham, July 2013 IX Publications and presentations Diagnostic criteria for erosive lichen planus affecting the vulva: An electronic-Delphi consensus exercise. THESIS’ (The Skin Investigation Society) Annual Meeting, London, June 2012 (Invited speaker) ‘Dreams, creams and aspirations’ British Society for the Study of Vulval Disease (BSSVD) Biannual Meeting, Newcastle, March 2012 Audit of current UK practice in the Diagnosis and Management of Vulval Erosive Lichen Planus; Results, Lessons and Future Work International Society for the Study of Vulval Disease (ISSVD) Biannual Meeting, Paris, September 2011 Vulval Erosive Lichen Planus. Results of a Cochrane Systematic review and subsequent Multi-centre case note audit X Grant awards and prizes arising from this work Year Award Role 2013 British Association of Presenter (oral Dermatologists 93rd Annual presentation)
Recommended publications
  • CPT® New Codes 2019: Biopsy, Skin

    CPT® New Codes 2019: Biopsy, Skin

    Billing and Coding Update Alexander Miller, M.D. AAD Representative to the AMA CPT Advisory Committee New Skin Biopsy CPT® Codes It’s all about the Technique! SPEAKER: Alexander Miller, M.D. AAD Representative to the AMA -CPT Advisory Committee Chair AAD Health Care Finance Committee Arriving on January 1, 2019 New and Restructured Biopsy Codes Tangential biopsy Punch Biopsy Incisional Biopsy How Did We Get Here? CMS CY 2016 Biopsy codes (11100, 11101 identified as potentially mis-valued; high expenditure RUC Survey sent to AAD Members Specialty survey results are the only tool available to support code values Challenging survey results Survey revealed bimodal data distribution; CPT Codes 11100, 11101 referred to CPT for respondents were valuing different procedures restructuring Rationale for New Codes 11100; 11101 • Previous skin biopsy codes did not distinguish between the different biopsy techniques that were being used CPT Recommended technique specification in new biopsy codes • Will also provide for reimbursement commensurate with the technique used How Did We Get Here? • CPT Editorial Panel deleted 11100; 11101 February 2017 • 6 New codes created based on technique utilized • Each technique: primary code and add-on code March 2017 • RUC survey sent to AAD members April 2017 • Survey results presented to the RUC Biopsy Codes Effective Jan., 1, 2019 • Integumentary biopsy codes 11755 Biopsy of nail unit (plate, bed, matrix, hyponychium, proximal and lateral nail folds 11100, 11101 have been deleted 30100 Biopsy, intranasal • New
  • ANMC Specialty Clinic Services

    ANMC Specialty Clinic Services

    Cardiology Dermatology Diabetes Endocrinology Ear, Nose and Throat (ENT) Gastroenterology General Medicine General Surgery HIV/Early Intervention Services Infectious Disease Liver Clinic Neurology Neurosurgery/Comprehensive Pain Management Oncology Ophthalmology Orthopedics Orthopedics – Back and Spine Podiatry Pulmonology Rheumatology Urology Cardiology • Cardiology • Adult transthoracic echocardiography • Ambulatory electrocardiology monitor interpretation • Cardioversion, electrical, elective • Central line placement and venous angiography • ECG interpretation, including signal average ECG • Infusion and management of Gp IIb/IIIa agents and thrombolytic agents and antithrombotic agents • Insertion and management of central venous catheters, pulmonary artery catheters, and arterial lines • Insertion and management of automatic implantable cardiac defibrillators • Insertion of permanent pacemaker, including single/dual chamber and biventricular • Interpretation of results of noninvasive testing relevant to arrhythmia diagnoses and treatment • Hemodynamic monitoring with balloon flotation devices • Non-invasive hemodynamic monitoring • Perform history and physical exam • Pericardiocentesis • Placement of temporary transvenous pacemaker • Pacemaker programming/reprogramming and interrogation • Stress echocardiography (exercise and pharmacologic stress) • Tilt table testing • Transcutaneous external pacemaker placement • Transthoracic 2D echocardiography, Doppler, and color flow Dermatology • Chemical face peels • Cryosurgery • Diagnosis
  • A Clinical and Histological Study of Radiofrequency-Assisted Liposuction (RFAL) Mediated Skin Tightening and Cellulite Improvement ——RFAL for Skin Tightening

    A Clinical and Histological Study of Radiofrequency-Assisted Liposuction (RFAL) Mediated Skin Tightening and Cellulite Improvement ——RFAL for Skin Tightening

    Journal of Cosmetics, Dermatological Sciences and Applications, 2011, 1, 36-42 doi:10.4236/jcdsa.2011.12006 Published Online June 2011 (http://www.SciRP.org/journal/jcdsa) A Clinical and Histological Study of Radiofrequency-Assisted Liposuction (RFAL) Mediated Skin Tightening and Cellulite Improvement ——RFAL for Skin Tightening Marc Divaris1, Sylvie Boisnic2, Marie-Christine Branchet2, Malcolm D. Paul3 1Plastic and Maxillo-Facial Surgery, University of Pitie Salpetiere, Paris, France; 2Institution GREDECO, Paris, France; 3Department of Surgery, Aesthetic and PlasticSurgery Institute, University of California, Irvine, USA. Email: [email protected] Received May 1st, 2011; revised May 27th, 2011; accepted June 6th, 2011. ABSTRACT Background: A novel Radiofrequency-Assisted Liposuction (RFAL) technology was evaluated clinically. Parallel origi- nal histological studies were conducted to substantiate the technology’s efficacy in skin tightening, and cellulite im- provement. Methods: BodyTiteTM system, utilizing the RFAL technology, was used for treating patients on abdomen, hips, flanks and arms. Clinical results were measured on 53 patients up to 6 months follow-up. Histological and bio- chemical studies were conducted on 10 donors by using a unique GREDECO model of skin fragments cultured under survival conditions. Fragments from RFAL treated and control areas were examined immediately and after 10 days in culture, representing long-term results. Skin fragments from patients with cellulite were also examined. Results: Grad- ual improvement in circumference reduction (3.9 - 4.9 cm) and linear contraction (8% - 38%) was observed until the third month. These results stabilized at 6 months. No adverse events were recorded. Results were graded as excellent by most patients, including the satisfaction from minimal pain, bleeding, and downtime.
  • Co™™I™™Ee Opinion

    Co™™I™™Ee Opinion

    The American College of Obstetricians and Gynecologists WOMEN’S HEALTH CARE PHYSICIANS COMMITTEE OPINION Number 673 • September 2016 (Replaces Committee Opinion No. 345, October 2006) Committee on Gynecologic Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice and the American Society for Colposcopy and Cervical Pathology (ASCCP) in collaboration with committee member Ngozi Wexler, MD, MPH, and ASCCP members and experts Hope K. Haefner, MD, Herschel W. Lawson, MD, and Colleen K. Stockdale, MD, MS. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Persistent Vulvar Pain ABSTRACT: Persistent vulvar pain is a complex disorder that frequently is frustrating to the patient and the clinician. It can be difficult to treat and rapid resolution is unusual, even with appropriate therapy. Vulvar pain can be caused by a specific disorder or it can be idiopathic. Idiopathic vulvar pain is classified as vulvodynia. Although optimal treatment remains unclear, consider an individualized, multidisciplinary approach to address all physical and emotional aspects possibly attributable to vulvodynia. Specialists who may need to be involved include sexual counselors, clinical psychologists, physical therapists, and pain specialists. Patients may perceive this approach to mean the practitioner does not believe their pain is “real”; thus, it is important to begin any treatment approach with a detailed discussion, including an explanation of the diagnosis and determination of realistic treatment goals. Future research should aim at evaluating a multimodal approach in the treatment of vulvodynia, along with more research on the etiologies of vulvodynia.
  • Japan Society of Gynecologic Oncology Guidelines 2015 for the Treatment of Vulvar Cancer and Vaginal Cancer

    Japan Society of Gynecologic Oncology Guidelines 2015 for the Treatment of Vulvar Cancer and Vaginal Cancer

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Tsukuba Repository Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer 著者 Saito Toshiaki, Tabata Tsutomu, Ikushima Hitoshi, Yanai Hiroyuki, Tashiro Hironori, Niikura Hitoshi, Minaguchi Takeo, Muramatsu Toshinari, Baba Tsukasa, Yamagami Wataru, Ariyoshi Kazuya, Ushijima Kimio, Mikami Mikio, Nagase Satoru, Kaneuchi Masanori, Yaegashi Nobuo, Udagawa Yasuhiro, Katabuchi Hidetaka journal or International Journal of Clinical Oncology publication title volume 23 number 2 page range 201-234 year 2018-04 権利 (C) The Author(s) 2017. This article is an open access publication This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons. org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. URL http://hdl.handle.net/2241/00151712 doi: 10.1007/s10147-017-1193-z Creative Commons : 表示 http://creativecommons.org/licenses/by/3.0/deed.ja Int J Clin Oncol (2018) 23:201–234 https://doi.org/10.1007/s10147-017-1193-z SPECIAL ARTICLE Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer Toshiaki Saito1 · Tsutomu Tabata2 · Hitoshi Ikushima3 · Hiroyuki Yanai4 · Hironori Tashiro5 · Hitoshi Niikura6 · Takeo Minaguchi7 · Toshinari Muramatsu8 · Tsukasa Baba9 · Wataru Yamagami10 · Kazuya Ariyoshi1 · Kimio Ushijima11 · Mikio Mikami8 · Satoru Nagase12 · Masanori Kaneuchi13 · Nobuo Yaegashi6 · Yasuhiro Udagawa14 · Hidetaka Katabuchi5 Received: 29 August 2017 / Accepted: 5 September 2017 / Published online: 20 November 2017 © The Author(s) 2017.
  • Comparison of the Management of Vaginal Complaints in General Practice to a Protocol

    Comparison of the Management of Vaginal Complaints in General Practice to a Protocol

    Comparison of the management of vaginal complaints in general practice to a protocol Introduction of the cervix, which are often caused by sexually transmitted pathogens, are less In the 'Standards' program of the Dutch easy to diagnose . Both a 'broad' approach College of General Practitioners, Stand­ and a strategy based on microbiological L. WIGERSMA ards (sets of guidelines) for quality medi­ diagnosis appear to besuitable for general cal care are developed.I 2 The Standards practice. The patient 's choice may often be Wigersma L. Comparison of the manage­ project was preceded by a research pro­ decisive . Variations in every phase of the ment of vaginal complaints in general prac­ gram for assessment of the feasibility and process ofcare can be accounted for. tice to a protocol. Huisarts Wet 1993; utility in daily practice of protocols for In this article, the diagnostic and thera­ 36(Suppl): 25·30. common conditions (the Protocols Pro­ peutic approach of vaginal disease in ject).' Decisive elements in the process of general practices in Amsterdam, the Abstract A protocol was developed for the problem solving (prior probability, prog­ Netherlands, is described and compared to approach of vaginal complaints, common con­ nosis, the efficacy of diagnostic tests and the corresponding elements of the proto­ ditions in general practice (GP). The manage­ ment of vaginal complaints in general practices treatments, and the influence of contextual col. The comparison specifically deals in Amsterdam, the Netherlands, was studied. factors such as the relationship between with the use and efficacy of office labora­ The diagnostic and therapeutic approach is de­ doctor and patient) are included in proto­ tory tests, microbiological tests, presump­ scribed and compared to the protocol.
  • Prevalence of Bacterial Vaginosis Among Patients with Vulvovaginitis in a Tertiary Hospital in Port Harcourt, Rivers State, Nigeria

    Prevalence of Bacterial Vaginosis Among Patients with Vulvovaginitis in a Tertiary Hospital in Port Harcourt, Rivers State, Nigeria

    Asian Journal of Medicine and Health 7(4): 1-7, 2017; Article no.AJMAH.36736 ISSN: 2456-8414 Prevalence of Bacterial Vaginosis among Patients with Vulvovaginitis in a Tertiary Hospital in Port Harcourt, Rivers State, Nigeria 1 1* 1 1 1 K. T. Wariso , J. A. Igunma , I. L. Oboro , F. A. Olonipili and N. Robinson 1Department of Medical Microbiology and Parasitology, University of Port Harcourt Teaching Hospital, Nigeria. Authors’ contributions This work was carried out in collaboration between the authors. Author KTW designed the study and wrote the protocol. Author FAO wrote the first draft of the manuscript. Authors JAI and NR managed the literature search and performed statistical analysis. Author ILO managed the analysis of the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/AJMAH/2017/36736 Editor(s): (1) Jaffu Othniel Chilongola, Department of Biochemistry & Molecular Biology, Kilimanjaro Christian Medical University College, Tumaini University, Tanzania. Reviewers: (1) Olorunjuwon Omolaja Bello, College of Natural and Applied Sciences, Wesley University Ondo, Nigeria. (2) Ronald Bartzatt, University of Nebraska, USA. Complete Peer review History: http://www.sciencedomain.org/review-history/21561 Received 12th September 2017 Accepted 12th October 2017 Original Research Article Published 25th October 2017 ABSTRACT Background: Bacterial vaginosis (BV) is one of the three common causes of vulvovaginitis in women of child bearing age, usually resulting from alteration the normal vaginal microbiota and PH. Common clinical presentation includes abnormal vaginal discharge, pruritus, dysuria and dyspareunia. Aims: To determine the prevalence of bacterial vaginosis among symptomatic women of child bearing age that attended various outpatient clinics in the university of Port Harcourt teaching Hospital.
  • Update on Vaginal Infections

    Update on Vaginal Infections

    PROGRESOS DE Obstetricia y Revista Oficial de la Sociedad Española Ginecología de Ginecología y Obstetricia Revista Oficial de la Sociedad Española de Ginecología y Obstetricia Prog Obstet Ginecol 2019;62(1):72-78 Revisión de Conjunto Update on vaginal infections: Aerobic vaginitis and other vaginal abnormalities Actualización en infecciones vaginales: vaginitis aeróbica y otras alteraciones vaginales Gloria Martín Saco, Juan M. García-Lechuz Moya Servicio de Microbiología. HGU Miguel Servet. Zaragoza Abstract It is estimated that abnormal vaginal discharge cannot be attributed to a clear infectious etiology in 15% to 50% of cases. Some women develop chronic vulvovaginal problems that are difficult to diagnose and treat, even by specialists. These disorders (aerobic vaginitis, desquamative inflammatory vaginitis, atrophic vaginitis, and cytolytic vaginosis) pose real challenges for clinical diagnosis and treatment. Researchers have established Key words: a diagnostic score based on phase-contrast microscopy. We review reported evidence on these entities and Vaginitis. present our diagnostic experience based on the correlation with Gram stain. We recommend treatment with Aerobic vaginitis. an antibiotic that has a very low minimum inhibitory concentration against lactobacilli and is effective against Parabasal cells. enterobacteria and Gram-positive cocci, which are responsible for these entities (aerobic vaginitis and desqua- Diagnosis. mative inflammatory vaginitis). Resumen Se estima que entre el 15 y el 50% de las mujeres que tienen trastornos del flujo vaginal, éstos no pueden atri- buirse a una etiología infecciosa clara. Algunas de ellas desarrollarán problemas vulvovaginales crónicos difíciles de diagnosticar y tratar, incluso por especialistas. Son trastornos que plantean desafíos reales en el diagnóstico Palabras clave: clínico y en su tratamiento como la vaginitis aeróbica, la vaginitis inflamatoria descamativa, la vaginitis atrófica y la vaginitis citolítica.
  • The Older Woman with Vulvar Itching and Burning Disclosures Old Adage

    The Older Woman with Vulvar Itching and Burning Disclosures Old Adage

    Disclosures The Older Woman with Vulvar Mark Spitzer, MD Itching and Burning Merck: Advisory Board, Speakers Bureau Mark Spitzer, MD QiagenQiagen:: Speakers Bureau Medical Director SABK: Stock ownership Center for Colposcopy Elsevier: Book Editor Lake Success, NY Old Adage Does this story sound familiar? A 62 year old woman complaining of vulvovaginal itching and without a discharge self treatstreats with OTC miconazole.miconazole. If the only tool in your tool Two weeks later the itching has improved slightly but now chest is a hammer, pretty she is burning. She sees her doctor who records in the chart that she is soon everyyggthing begins to complaining of itching/burning and tells her that she has a look like a nail. yeast infection and gives her teraconazole cream. The cream is cooling while she is using it but the burning persists If the only diagnoses you are aware of She calls her doctor but speaks only to the receptionist. She that cause vulvar symptoms are Candida, tells the receptionist that her yeast infection is not better yet. The doctor (who is busy), never gets on the phone but Trichomonas, BV and atrophy those are instructs the receptionist to call in another prescription for teraconazole but also for thrthreeee doses of oral fluconazole the only diagnoses you will make. and to tell the patient that it is a tough infection. A month later the patient is still not feeling well. She is using cold compresses on her vulva to help her sleep at night. She makes an appointment. The doctor tests for BV.
  • Insights Into the Urogenial Microbiome of Females Suffering from Infectious

    Insights Into the Urogenial Microbiome of Females Suffering from Infectious

    From the Department of Infectious Diseases and Microbiology of the University of Lübeck Director: Prof. Dr. med. Jan Rupp The cervical microbiome in female infectious infertility: clinical trial and experimental mouse models Dissertation for Fulfillment of Requirements for the Doctoral Degree of the University of Lübeck from the Department of Natural Sciences Submitted by Simon Graspeuntner from Oberndorf b. Sbg. (Austria) Lübeck 2016 First referee: Prof. Dr. med. Jan Rupp Second referee: Prof. Dr. rer. nat. Ulrich Schaible Date of oral examination: 26.06.2017 Approved for printing: Lübeck, 06.07.2017 Table of content P a g e | I Table of content Abstract ........................................................................................................................... 1 Zusammenfassung .......................................................................................................... 3 1 Introduction .................................................................................................................... 5 1.1 Female infectious infertility ............................................................................................. 5 1.1.1 Female infertility is an important worldwide health issue .............................................. 5 1.1.2 Sexually transmitted diseases cause tubal factor infertility ............................................ 5 1.2 The microbiome of the female urogenital tract .............................................................. 7 1.2.1 Characterization of the vaginal microbiota
  • Slide Courtesy of Jeff North, MD

    Slide Courtesy of Jeff North, MD

    3/17/2017 Basic Dermatology Procedures Basic Dermatology Procedures for the Non‐dermatologist • Liquid Nitrogen • Skin Biopsies Lindy P. Fox, MD • Electrocautery Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco [email protected] I have no conflicts of interest to disclose 1 Liquid Nitrogen Cryosurgery 1 3/17/2017 Liquid Nitrogen Cryosurgery Liquid Nitrogen Cryosurgery Principles • Indications • ‐ 196°C (−320.8°F) – Benign, premalignant, in situ malignant lesions • Temperatures of −25°C to −50°C (−13°F to −58°F) within 30 seconds with spray or probe • Objective – Selective tissue necrosis • Benign lesions: −20°C to −30°C (−4°F to −22°F) • Reactions predictable • Malignant lesions: −40°C to −50°C. – Crust, bulla, exudate, edema, sloughing • Post procedure hypopigmentation • Rapid cooling intracellular ice crystals • Slow thawing tissue damage – Melanocytes are more sensitive to freezing than • Duration of THAW (not freeze) time is most keratinocytes important factor in determining success Am Fam Physician. 2004 May 15;69(10):2365‐2372 Liquid Nitrogen Cryosurgery • Fast freeze, slow thaw cycles – Times vary per condition (longer for deeper lesion) – One cycle for benign, premalignant – Two cycles for warts, malignant (not commonly done) • Lateral spread of freeze (indicates depth of freeze) – Benign lesions 1‐2mm beyond margins – Actinic keratoses‐ 2‐3mm beyond margins – Malignant‐ 3‐5+mm beyond margins (not commonly done) From: Bolognia, Jorizzo, and Schaffer.
  • SKIN GRAFTS and SKIN SUBSTITUTES James F Thornton MD

    SKIN GRAFTS and SKIN SUBSTITUTES James F Thornton MD

    SKIN GRAFTS AND SKIN SUBSTITUTES James F Thornton MD HISTORY OF SKIN GRAFTS ANATOMY Ratner1 and Hauben and colleagues2 give excel- The character of the skin varies greatly among lent overviews of the history of skin grafting. The individuals, and within each person it varies with following highlights are excerpted from these two age, sun exposure, and area of the body. For the sources. first decade of life the skin is quite thin, but from Grafting of skin originated among the tilemaker age 10 to 35 it thickens progressively. At some caste in India approximately 3000 years ago.1 A point during the fourth decade the thickening stops common practice then was to punish a thief or and the skin once again begins to decrease in sub- adulterer by amputating the nose, and surgeons of stance. From that time until the person dies there is their day took free grafts from the gluteal area to gradual thinning of dermis, decreased skin elastic- repair the deformity. From this modest beginning, ity, and progressive loss of sebaceous gland con- skin grafting evolved into one of the basic clinical tent. tools in plastic surgery. The skin also varies greatly with body area. Skin In 1804 an Italian surgeon named Boronio suc- from the eyelid, postauricular and supraclavicular cessfully autografted a full-thickness skin graft on a areas, medial thigh, and upper extremity is thin, sheep. Sir Astley Cooper grafted a full-thickness whereas skin from the back, buttocks, palms of the piece of skin from a man’s amputated thumb onto hands and soles of the feet is much thicker.